Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference

GlobeNewswire August 1, 2018

KemPharm, Inc. to Report Second Quarter 2018 Results

GlobeNewswire July 31, 2018

KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD

GlobeNewswire July 9, 2018

KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results

GlobeNewswire May 10, 2018

KemPharm, Inc. to Report First Quarter 2018 Results

GlobeNewswire May 1, 2018

KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD

GlobeNewswire October 4, 2017

KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate

GlobeNewswire September 20, 2017

KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA

GlobeNewswire September 12, 2017

KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

GlobeNewswire August 31, 2017

Investor Network: KemPharm, Inc. to Host Earnings Call

Accesswire August 10, 2017

KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety

GlobeNewswire August 8, 2017

KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference

GlobeNewswire August 3, 2017

KemPharm, Inc. to Report Second Quarter 2017 Results

GlobeNewswire August 1, 2017

KemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate

GlobeNewswire June 28, 2017

KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone

GlobeNewswire June 26, 2017

KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids

GlobeNewswire June 9, 2017

KemPharm Announces Addition to Leadership Team

GlobeNewswire June 1, 2017

KemPharm, Inc. Reports First Quarter 2017 Results

GlobeNewswire May 10, 2017

Investor Network: KemPharm, Inc. to Host Earnings Call

Accesswire May 10, 2017

KemPharm, Inc. to Report First Quarter 2017 Results

GlobeNewswire May 1, 2017